Advertisement
Canada markets closed
  • S&P/TSX

    21,611.30
    +23.42 (+0.11%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CAD/USD

    0.7291
    -0.0000 (-0.00%)
     
  • CRUDE OIL

    81.54
    -0.03 (-0.04%)
     
  • Bitcoin CAD

    89,881.35
    +1.52 (+0.00%)
     
  • CMC Crypto 200

    1,351.30
    -38.11 (-2.74%)
     
  • GOLD FUTURES

    2,343.50
    -3.40 (-0.14%)
     
  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     
  • 10-Yr Bond

    4.2170
    -0.0620 (-1.45%)
     
  • NASDAQ futures

    19,947.50
    +28.25 (+0.14%)
     
  • VOLATILITY

    12.30
    -0.45 (-3.53%)
     
  • FTSE

    8,191.29
    +49.14 (+0.60%)
     
  • NIKKEI 225

    38,707.21
    +225.10 (+0.58%)
     
  • CAD/EUR

    0.6786
    +0.0001 (+0.01%)
     

Arcturus Therapeutics Holdings First Quarter 2024 Earnings: Beats Expectations

Arcturus Therapeutics Holdings (NASDAQ:ARCT) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$38.0m (down 53% from 1Q 2023).

  • Net loss: US$26.8m (down by 153% from US$50.8m profit in 1Q 2023).

  • US$1.00 loss per share (down from US$1.91 profit in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Arcturus Therapeutics Holdings Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 115%. Earnings per share (EPS) also surpassed analyst estimates by 19%.

Looking ahead, revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

ADVERTISEMENT

Performance of the American Biotechs industry.

The company's shares are up 2.6% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Arcturus Therapeutics Holdings' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.